Marketing Ability Could Become Decisive Factor as All DPP-4 Inhibitors Are Likely to Obtain the Same Concurrent-use Indications

A number of drug makers are hurrying to gain concurrent-use indications for their DPP-4 inhibitors. Manufacturers of three products including Equa (vildagliptin) plan to obtain multiple indications at once through the “long-term administration studies of concurrent therapies” described in the...read more